|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1992-5-13
|
|
pubmed:abstractText |
Tumor-infiltrating lymphocytes (TIL) were obtained from a mouse melanoma cell line (CL 62) transfected with the gene for the human melanoma Ag p97. TIL were cultured with anti-CD3 antibody and IL-2 for up to 38 days. Flow cytometry identified these TIL as Thy-1.2 + ve/CD4-ve/CD8 + ve cells. A heteroconjugated antibody 500A2 x 96.5, specific for both the CD3 Ag on TIL and the p97 Ag on CL 62 melanoma cells, was prepared using N-succinimidyl-3-(2-pyridyldithio)-propionate as a linking agent. TIL alone demonstrated low levels of cytotoxicity against autologous CL 62 tumor and also against the parental K1735 tumor and an allogeneic murine melanoma (B16). The addition of 500A2 x 96.5 heteroconjugated antibody enhanced TIL-mediated lysis of CL 62 tumor, but not of the K1735 or B16 tumors. This enhanced cytotoxicity was elicited at E:T ratios as low as 0.4:1, and in TIL cultured for 7 to 38 days. These results suggest that hetero-conjugated antibody may enhance the anti-tumor effect of TIL in vivo.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Melanoma-Specific Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
148
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2630-5
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1532818-Animals,
pubmed-meshheading:1532818-Antibodies, Monoclonal,
pubmed-meshheading:1532818-Antibodies, Neoplasm,
pubmed-meshheading:1532818-Antigens, CD3,
pubmed-meshheading:1532818-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:1532818-Antigens, Neoplasm,
pubmed-meshheading:1532818-Cytotoxicity, Immunologic,
pubmed-meshheading:1532818-Female,
pubmed-meshheading:1532818-Humans,
pubmed-meshheading:1532818-Immunotherapy,
pubmed-meshheading:1532818-Lymphocyte Activation,
pubmed-meshheading:1532818-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:1532818-Melanoma,
pubmed-meshheading:1532818-Melanoma, Experimental,
pubmed-meshheading:1532818-Melanoma-Specific Antigens,
pubmed-meshheading:1532818-Mice,
pubmed-meshheading:1532818-Mice, Inbred BALB C,
pubmed-meshheading:1532818-Mice, Inbred C3H,
pubmed-meshheading:1532818-Neoplasm Proteins,
pubmed-meshheading:1532818-Receptors, Antigen, T-Cell
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
|
|
pubmed:affiliation |
Department of Surgery, Mayo Clinic, Rochester, MN 55905.
|
|
pubmed:publicationType |
Journal Article
|
